Our clinical studies
We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.
Clinical studies
This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.
Total studies
Current studies
Oncology
Dermatology
Rare diseases
Others
| Title | Therapeutic area | Phase | Status | Start date | Planned End date |
|---|---|---|---|---|---|
Study of FIH of STX-241 in locally advanced or metastatic NSCLC resistant to EGFR TKIs (STX-241FIH) |
Oncology | Phase I / II | Active | September 17, 2024 | July 2030 |
Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group. |
Oncology | Phase III | Completed | May 18, 2022 | November 19, 2024 |
Get access to Partner's pivotal studies supporting our authorized drugs in Europe
Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below: